Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04372433
Title IO-202 as Monotherapy and IO-202 Plus Azacitidine +/- Venetoclax in Patients in AML and CMML
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Immune-Onc Therapeutics Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University California, Davis (117) Davis California 95817 United States Details
City of Hope (106) Duarte California 91010 United States Details
University of California, Irvine (107) Irvine California 92868 United States Details
UCLA, Medical Center Division of Hematology/Oncology (119) Los Angeles California 90095 United States Details
Stanford University (114) Palo Alto California 94305 United States Details
University of California, San Francisco (118) San Francisco California 94143 United States Details
University of Colorado, Anschutz Medical Campus (103) Aurora Colorado 80045 United States Details
Winship Cancer Institute of Emory University (105) Atlanta Georgia 30322 United States Details
The University of Chicago (113) Chicago Illinois 60637 United States Details
Weill Cornell Medical College, New York Presbyterian Hospital (110) New York New York 10021 United States Details
Cleveland Clinic, Taussig Cancer Institute (111) Cleveland Ohio 44195 United States Details
Oregon Health and Science University, Center for Hematologic Malignancies (116) Portland Oregon 97239 United States Details
University of Texas Southwestern, Simmons Comprehensive Cancer Center (104) Dallas Texas 75390 United States Details
MD Anderson Cancer Center (101) Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field